Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.
Williams PM, Forbes T, P Lund S, Cole KD, He HJ, Karlovich C, Paweletz CP, Stetson D, Yee LM, Connors DE, Keating SM, Destenaves B, Cleveland MH, Lau CJ, Barrett JC, Kelloff GJ, McCormack RT. Williams PM, et al. Among authors: karlovich c. JCO Precis Oncol. 2021 Jun 1;5:PO.20.00528. doi: 10.1200/PO.20.00528. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250423 Free PMC article.
Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.
He HJ, Stein EV, Konigshofer Y, Forbes T, Tomson FL, Garlick R, Yamada E, Godfrey T, Abe T, Tamura K, Borges M, Goggins M, Elmore S, Gulley ML, Larson JL, Ringel L, Haynes BC, Karlovich C, Williams PM, Garnett A, Ståhlberg A, Filges S, Sorbara L, Young MR, Srivastava S, Cole KD. He HJ, et al. Among authors: karlovich c. J Mol Diagn. 2019 Jul;21(4):658-676. doi: 10.1016/j.jmoldx.2019.03.006. Epub 2019 May 2. J Mol Diagn. 2019. PMID: 31055023 Free PMC article.
Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements.
He HJ, Das B, Cleveland MH, Chen L, Camalier CE, Liu LC, Norman KL, Fellowes AP, McEvoy CR, Lund SP, Almeida J, Steffen CR, Karlovich C, Williams PM, Cole KD. He HJ, et al. Among authors: karlovich c. Clin Chem Lab Med. 2019 Jul 26;57(8):1142-1152. doi: 10.1515/cclm-2018-1306. Clin Chem Lab Med. 2019. PMID: 31112502 Free PMC article.
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O'Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih CJ, Polley E, Simon R, Li MC, Piekarz R, Doroshow JH. Chen AP, et al. Among authors: karlovich c. JCO Precis Oncol. 2021 Jan 12;5:PO.20.00372. doi: 10.1200/PO.20.00372. eCollection 2021. JCO Precis Oncol. 2021. PMID: 33928209 Free PMC article. Clinical Trial.
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors.
Bonner ER, Harrington R, Eze A, Bornhorst M, Kline CN, Gordish-Dressman H, Dawood A, Das B, Chen L, Pauly R, Williams PM, Karlovich C, Peach A, Howell D, Doroshow J, Kilburn L, Packer RJ, Mueller S, Nazarian J. Bonner ER, et al. Among authors: karlovich c. NPJ Precis Oncol. 2022 Sep 6;6(1):63. doi: 10.1038/s41698-022-00306-3. NPJ Precis Oncol. 2022. PMID: 36068285 Free PMC article.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. Karlovich C, et al. Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8. Clin Cancer Res. 2016. PMID: 26747242 Free PMC article. Clinical Trial.
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. Goldman JW, et al. Among authors: karlovich c. JCO Precis Oncol. 2018 Nov;2:1-13. doi: 10.1200/PO.17.00116. JCO Precis Oncol. 2018. PMID: 35135111
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. Conley BA, et al. Among authors: karlovich c. J Natl Cancer Inst. 2021 Jan 4;113(1):27-37. doi: 10.1093/jnci/djaa061. J Natl Cancer Inst. 2021. PMID: 32339229 Free PMC article.
33 results